Cytomegalovirus (CMV) pneumonia is reportedly unusual among adults with leukemia who have not undergone transplantation. To assess the frequency of CMV pneumonia and its outcome during the present time, we reviewed the experience of 2136 hospitalized adults with leukemia. Sixty-one patients (2.9%) had CMV pneumonia diagnosed. The frequency doubled from 1.4% in 1992-1994 to 2.8% in 1995-1997 ( ). P ! .05 Fifty-four patients (89%) had received treatment with an immunosuppressive chemotherapeutic regimen that contained fludarabine ( ), high-dose cytoxan ( ), or both ( ), and 15 patients (25%) had n p 37 n p 17 n p 10 received granulocyte transfusions that were stimulated with hematopoietic growth factors from unscreened donors. The overall CMV pneumonia-associated mortality rate was 57%. Among autopsied patients who had leukemia, the frequency of CMV pneumonia increased from 0%,
who were cared for at the Memorial and James Ewing Hospital (New York) during a 12-year period from 1957 through 1968, only 19 cases (0.3%) of CMV disease were identified, 17 of which involved the lung [2] . Similarly, in an autopsy review of 9029 adults with cancer cared for at the University of Texas M. D. Anderson Cancer Center (MDACC, Houston) during a 27-year period from January 1964 through December 1990, only 20 cases of CMV pneumonia (0.2%) were identified [9] . Among 1607 adults with leukemia, the frequency of cases of CMV pneumonia was 0.4%.
During the past decade, advances have been made in the therapy for and supportive care of patients with leukemia. Among these advances is the use of drugs that cause profound and prolonged cell-mediated immunosuppression, such as fludarabine and high-dose cyclophosphamide [12] [13] [14] . In addition, granulocyte transfusions from donors who have not been screened for CMV disease and whose granulocyte counts have been stimulated with hematopoietic growth factors have been used more liberally, both as prophylaxis and therapy [15] . These changes have been associated with a change in the spectrum of organisms to which these patients are vulnerable [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . In addition to the traditional bacterial and fungal pathogens that take advantage of chemotherapyinduced granulocytopenia, infections due to organisms that take advantage of cell-mediated immunodeficiency, such as Pneumocystis carinii pneumonia, mycobacteriosis, cryptococcosis, listeriosis, and herpes zoster virus infections, are being observed with increased frequency. Invasive CMV infections have also been reported sporadically [13, 16, 21, 23, 25] .
At MDACC, it is our clinical impression that, among patients with hematologic malignancies, the frequency of serious CMV disease, and of CMV pneumonia in particular, escalated steadily during the 1990s. To systematically assess both the frequency of CMV pneumonia in adults with leukemia who have not undergone transplantation and the outcome of such cases during the present time, the experience at MDACC from July 1992 through December 1997 was reviewed.
MATERIALS AND METHODS
We reviewed the virology records and autopsy reports of all adults with leukemia who had not undergone transplantation hospitalized at MDACC during the period from 1 July 1992 through 31 December 1997. For those patients who were identified as having CMV pneumonia, medical records for up to 6 months after the onset of pneumonia were reviewed.
During the study period, viral blood cultures and bronchoscopic evaluations were performed, at the discretion of the primary physician, for detection of symptomatic disease. Blood and bronchoalveolar lavage (BAL) samples were assayed for CMV by means of shell vial centrifugation and conventional viral cultures.
"CMV pneumonia" was defined as the occurrence of clinical and radiographic evidence of pneumonia, in association with the isolation of CMV in viral cultures of BAL or lung-tissue specimens or with the identification of CMV in lung tissue by means of characteristic histopathology or immunohistochemistry. Concurrent identification of another pathogen was not considered to be an exclusion criterion because of the wellestablished frequency of polymicrobic infections in this patient population. The "onset of pneumonia" was defined as the day of onset of the respiratory illness. "CMV pneumonia-associated death" was defined as death due to the progressive respiratory failure of a patient who had CMV identified either in BAL fluid or a lung tissue specimen or in a postmortem lung tissue. "Concurrent infections" were defined as other potentially lifethreatening infections that occurred within 30 days of the episode of CMV pneumonia. "Neutropenia" was defined as a neutrophil count of р500 neutrophils/mL of blood. "Lymphopenia" was defined as a lymphocyte count of р200 lymphocytes/mL of blood.
Therapy consisted of administration of iv ganciclovir, 5 mg/ kg iv q12h, and standard iv Ig, 500 mg/kg given every other day, for у21 days. Foscarnet was substituted for ganciclovir, when necessary, to avoid the myelosuppressive effects of ganciclovir, 60 mg/kg iv q8h, adjusted for renal function. The response to therapy was considered evaluable if it was administered for at least 48 h.
Differences between variables were analyzed by means of Fisher's exact test (2-tailed) or the x 2 test. The underlying diseases and stage of disease are shown in tables 1 and 2. The frequency of CMV pneumonia ranged from a low of 0.4%, 2.2%, 2.3%, and 2.5% in patients with myelodysplastic syndrome, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), and acute lymphocytic leukemia (ALL), respectively, to a high of 8.8% and 11.4% in patients with chronic lymphocytic leukemia (CLL) and lymphoblastic lymphoma, respectively ( ). In 36 patients (59%), the leukemia P ! .05 was either relapsed, refractory, or in an accelerated or blast phase; in 25 patients (41%), the leukemia was newly diagnosed or in complete or partial remission. The median duration of time from the diagnosis of leukemia to the occurrence of CMV pneumonia ranged from 6 months and 9 months in patients with AML and ALL, respectively, to 25 months and 54 months in patients with CML and CLL, respectively. All 28 patients for whom CMV serological tests were performed before the onset of pneumonia were seropositive for CMV.
RESULTS

From
Fifty-four patients (89%) had previously received treatment with a chemotherapeutic regimen that contained fludarabine ( ), high-dose cytoxan ( ), or both ( ). n p 37 n p 17 n p 10 Twenty-five (68%) of the 37 patients who had received fludarabine had also received high doses of steroids. Within the preceding month, 15 patients (25%) had received transfusions of irradiated granulocytes from donors whose granulocyte counts had been stimulated with hematopoietic growth factors and who had not been screened for CMV infection. All 15 patients had received fludarabine or high-dose cytoxan.
The mean age of the 20 patients with CLL was 63 years (range, 47-80 years). In 19 patients (95%), the leukemia was relapsed or refractory. All 20 patients had received at least 3 courses of therapy with fludarabine ( ), high doses of n p 20 steroids ( ), and/or granulocyte transfusions ( ). n p 13 n p 3 Among the 18 patients with AML, 14 (78%) had received flu- darabine ( ), granulocyte transfusions ( ), or both n p 7 n p 3 ( ). Of the 8 patients with ALL, 4 (50%) had received n p 4 fludarabine ( ) or granulocyte transfusions ( ). n p 1 n p 3 The overall CMV pneumonia-associated mortality rate was 57%. Death occurred a mean of 15 days (range, 2-36 days) after the onset of pneumonia. Six months after the onset of pneumonia, the overall mortality rate was 82%. In 22 (63%) of the 35 fatal cases, the leukemia was relapsed, refractory, or was in an accelerated phase or blast phase. In the other 13 fatal cases (37%), the leukemia was newly diagnosed or was in partial or complete remission. An autopsy was performed on 8 of these 13 patients, and the diagnosis of CMV pneumonia was confirmed in 7 patients.
Thirty-nine patients (64%) with CMV pneumonia received antiviral therapy with ganciclovir (or foscarnet) and iv immunoglobulin (table 3) . The overall mortality rate among treated patients was 62%. Among 29 patients for whom therapy was initiated before the occurrence of respiratory failure that required mechanical ventilation, the mortality rate was 48%. Among 10 patients for whom therapy was initiated after the occurrence of respiratory failure that required mechanical ventilation, the mortality rate was 100% ( ). P ! .05 Of the 22 patients who did not receive antiviral therapy, 11 (50%) died. Thirteen patients were not treated because the respiratory illness had substantially improved by the time the diagnosis became available and/or because the clinical-radiographic picture was not considered to be compatible with viral pneumonia. Two of these patients died of progressive pneumonia. Nine patients, all of whom died, were not treated either because the diagnosis was made postmortem ( ) or within n p 7 1 day of death ( ) or because the patient declined further n p 1 treatment ( ). n p 1 The CMV pneumonia-associated mortality rate was significantly higher among patients with lymphopenia than among patients without lymphopenia (78% vs. 49%, respectively;
; table 2). There was a trend toward a higher mortality P ! .05 rate among patients with neutropenia than among patients without neutropenia (73% vs. 52%, respectively).
Twenty-six patients had at least 1 serious concurrent pulmonary infection: 15 had infections due to opportunistic molds, including Aspergillus species ( ), Mucorales n p 12 ( ), and Fusarium species ( ); 9 patients had infecn p 2 n p 1 tions due to viruses, including respiratory syncytial virus ( ), parainfluenza virus ( ), influenza virus ( ), n p 2 n p 2 n p 1 picornavirus ( ), adenovirus ( ), and mixed adenon p 1 n p 1 virus/picornavirus ( ); and 4 patients had infections due n p 1 to Legionella species ( ), Mycobacterium tuberculosis n p 1 ( ), or enterococci ( ). The CMV pneumon p 1 n p 2 nia-associated mortality rate was significantly higher among these 26 patients than among the 35 patients without concurrent pulmonary infections (77% vs. 43%, respectively;
). P ! .5 In the 61 cases of CMV pneumonia, the diagnosis was made as follows: by premortem culture of BAL fluid ( ) or lung n p 47 tissue specimens ( ); by premortem culture of BAL fluid n p 1 with postmortem confirmation by characteristic pulmonary histopathology ( ) or immunohistochemistry ( ); by n p 4 n p 1 postmortem characteristic pulmonary histopathology ( ; n p 5 preceded by CMV viremia in 2 cases); by postmortem culture of lung tissue specimens and characteristic or consistent pulmonary histopathology ( ); and by postmortem culture n p 2 of lung tissue specimens and immunohistochemistry ( ). n p 1 Three of the 8 patients who had CMV pneumonia diagnosed only at postmortem examination had undergone BAL, which had revealed CMV in none of them. In 2 of the 47 patients who had CMV pneumonia diagnosed only by cultures of BAL fluid, a postmortem examination was performed; it revealed only aspergillosis in each case.
Fourteen of the 61 patients had shell-vial viral blood cultures performed within 7 days preceding the onset of CMV pneumonia. CMV viremia was detected in 7 patients (50%).
Among adults with leukemia who died and on whom autopsies were performed, the frequency of CMV pneumonia increased from 0%, 2.3%, and 0% in 1992, 1993, and 1994, respectively, to 4.6%, 6.5%, and 16% in 1995, 1996, and 1997, respectively ( ; table 1 ). Four of the 13 patients whose CMV pneumonia P ! .05 was confirmed at postmortem examination were found to have had disseminated CMV disease. Three of the 13 patients were found to have had concurrent pulmonary infections, including enterococcal pneumonia ( ) and localized mucormycoses n p 1 ( ). The underlying diseases of these 13 patients were CML n p 2 ( ), CLL ( ), AML ( ), ALL ( ), and lymn p 5 n p 2 n p 3 n p 2 phoblastic lymphoma ( ). All 13 patients had received treatn p 1 ment with a chemotherapeutic regimen that included fludarabine and/or high-dose cytoxan, and 5 had received granulocyte transfusions. During this time, nonpulmonary invasive CMV disease was found at autopsy in only 2 other adults with leukemia, both of whom had CMV adrenalitis.
DISCUSSION
CMV has emerged as an important cause of life-threatening pneumonia among adults with leukemia who have not undergone transplantation. This change has occurred during an era of increasing use of immunosuppressive chemotherapeutic agents that cause severe and prolonged suppression of cellmediated immunity, in addition to traditional myelosuppression. Among the new chemotherapeutic regimens are purine nucleoside analogs, such as fludarabine monophosphate, which causes a profound decline in T lymphocytes (and, in particular, CD4 lymphocytes) that may persist for years [22, 24, 27, 29] . In addition, well-established potent immunosuppressive drugs, such as cytoxan, are being administered in higher doses. Other immunosuppressive agents that cause profound lymphopenia are also being investigated, including other purine nucleoside analogs (such as 2-chlorodeoxyadenosine [CdA] and 2 deoxycoformycin [DCF]) and CAMPATH-1H (a humanized anti-CD52 monoclonal antibody that binds to the cell membrane of most human blood lymphocytes, as well as that of most B and T cell lymphomas) [29, 32, 33] . Frequently, the patients are exposed to several potent immunosuppressive agents, including high doses of steroids. Other factors that potentially contribute to the increased frequency of CMV disease include a heightened interest in and surveillance for viral infections and the more routine availability of improved diagnostic techniques. In addition, granulocyte transfusions that have been obtained from donors who have not been screened for CMV infection and that have been stimulated with hematopoietic growth factors are being used more liberally, both prophylactically and therapeutically. In this study, one-quarter of the patients with CMV pneumonia had received such transfusions. Granulocyte transfusions have long been recognized as an important mode of transmission of CMV infections, although their role in primary infections in seronegative recipients is more clearly established than that in latent CMV infections in seropositive recipients [34, 35] . In this study, all tested patients were seropositive at baseline, which suggests reactivation of latent infection.
Children with leukemia have been reported to have a high frequency of active CMV infection (range, 27%-46%) but a relatively low frequency of serious CMV disease (range, 3%-5%) [36] [37] [38] [39] [40] [41] . With regard to adults with leukemia, scant data are available on the frequency of asymptomatic, active CMV infection. Life-threatening CMV disease has been reported to be uncommon, occurring in !1% of patients [2, 9] . The exception has been for patients with T cell leukemia, in whom serious CMV disease, primarily pneumonia, has been found at autopsy in 17%-75% of cases [3, 4, 7] .
In the current study, the overall frequency of CMV pneumonia in adults with leukemia increased twofold, from 1.4% during 1992-1994 to 2.8% in 1995-1997 ( ). Although the overall P ! .5 frequency was relatively low, the frequency was as high as 9% in some subsets of patients, such as patients with CLL. The question arises as to whether such subsets of patients (in particular, those who have been treated with potent immunosuppressive drugs) should receive antiviral prophylaxis. The prolonged interval (15 years) between the diagnosis of CLL and the onset of CMV pneumonia and the toxicity of the prophylactic agents that are currently available, however, highlight the need for further risk stratification. A strategy of preemptive therapy might be an option; however, the sensitivity and specificity of asymptomatic shedding of CMV in the blood or bodily fluids (such as BAL fluid) of adults with leukemia remains to be clarified.
Among patients who died and on whom autopsies were performed, the frequency rate of CMV pneumonia increased dramatically, from 0.4% in 1964-1990 [9] and 0.7% in 1992-1994, to 8.8% in 1995-1997 ( ). In 1997, the rate of frequency P ! .05 of CMV pneumonia noted at autopsy reached a high of 16%. In one-third of the cases found at autopsy, CMV pneumonia was associated with disseminated CMV disease. During the study period, only 2 other adults with leukemia who underwent autopsy were found to have nonpulmonary CMV disease, which indicated that, in adults with leukemia who have not undergone transplantation, as in bone-marrow transplant recipients, pneumonia is the most frequent serious manifestation of CMV infection.
The overall CMV pneumonia-associated mortality rate was high (57%). A notable finding was that one-quarter of the cases involved patients with complete remission, and the mortality rate was also high (43%) among these patients. The mortality rate was significantly higher among patients who had lymphopenia, which highlights the important role of lymphocytes in the control of viral infections.
Among patients treated aggressively with a combination of ganciclovir or foscarnet and iv Ig during an early stage of the pneumonia, the mortality rate was 44%. In contrast, therapy initiated after the onset of respiratory failure was associated with a mortality rate of 100%. Since there are no published reports of historical controls among adults with leukemia, the added benefit of combination therapy could not be evaluated.
Eleven cases of CMV pneumonia (18%), as defined by the study criteria, resolved without specific antiviral therapy. For study purposes, patients were considered to have CMV pneumonia if CMV was isolated from BAL fluid in association with clinical and radiographic pneumonia. However, the sensitivity and specificity of isolation of CMV from BAL fluid obtained from adults with leukemia are not known. The findings in this study suggest that, for patients with leukemia who have not undergone transplantation, the isolation of CMV from BAL fluid may occasionally reflect colonization or oropharyngeal contamination, rather than invasive pulmonary disease. In some adults with leukemia with more intact immunity, CMV pneumonia may occasionally be self-limited. Nonetheless, the histopathologic documentation of invasive CMV pneumonia in lung specimens obtained from 120% of the patients and the dramatic increase in the frequency of documented CMV pneumonia in adults with leukemia on whom autopsies were performed at MDACC from 1960 through 1997, give testimony to the increasing frequency of invasive CMV pneumonia.
In conclusion, CMV has emerged as an important cause of life-threatening pneumonia in adults with leukemia and, in particular, those patients who have received lymphocytotoxic immunosuppressive therapies. It is important to be cognizant of this so that the diagnosis can be pursued aggressively and therapy can be initiated during an early stage of the respiratory illness. Even with the prompt initiation of therapy, the mortality rate associated with pneumonia was considerable. Alternative approaches need to be explored, including a combination of antiviral drugs and immunotherapy, preemptive therapy for asymptomatic viral shedding, chemoprophylaxis and/or immunoprophylaxis, and screening of granulocyte transfusions for CMV infections. Clinical risk factors for CMV disease will need to be further defined in controlled trials so that prophylactic and preemptive strategies can be targeted rationally. These risks will need to be continually reassessed, because the acquired and cumulative immunodeficiencies of patients with hematologic malignancies are in a state of flux and they reflect changing chemotherapeutic and supportive-care regimens.
